All News
Serious Infections Still Common in Vasculitis
Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.
Read Article
RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
Read Article
Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights
In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning.
Read Article
Safety of Paternal DMARD or Biologic Use
A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.
Read Article
RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout
Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.
Read Article
Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Read Article
RheumNow Podcast – Great Associations (3.19.2021)
Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.
Read Article
Enthesitis Responses to Secukinumab in Spondylitis Patients
Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.
Read Article
Rheumatic Patients Are at Risk for COVID Death
Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun
Read Article
Comparison of Three Coronavirus Vaccines
On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available. We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth.
Read Article
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
122 Adult onset Still's disease pts followed a median of 12 mos shows 21% with >=1 relapses. The cumulative relapse rate was 29% at 36 mos. Relapses increased w intensive Rx (OR 6.8) & MAS (OR 4.0)."Intensive" refers to steroids plus DMARDs - not biologics https://t.co/BRKi5sUQQZ
Links:
Dr. John Cush RheumNow ( View Tweet)
